• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阐明Ras蛋白作为炎症和癌症的双重治疗靶点:综述

Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.

作者信息

Nandan Parmar Keshri, Sivaraman Jayanthi

机构信息

School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India.

出版信息

Discov Oncol. 2025 Jun 7;16(1):1029. doi: 10.1007/s12672-025-02783-x.

DOI:10.1007/s12672-025-02783-x
PMID:40483365
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12145382/
Abstract

Cancer, one of the most dreadful diseases of the twenty-first century develops as a result of unregulated inflammatory responses and mutations of genes. In human cancers, among various mutated genes, the Ras gene is one of the most commonly mutated oncogenes. However, when it comes to inflammation, oncogenic Ras mutants can induce tumorigenesis without tumour suppression loss driven by inflammatory responses. Ras protein is a membrane-bound protein with inbuilt GTPase activity which is activated by a variety of extracellular stimuli, converting from an inactive form to an active form. Oncogenic Ras mutants is continuously activated in cancer, thereby enhancing aberrant downstream signalling that leads to tumorigenesis. So, to highlight the significance of Ras protein in cancer and inflammation, this review discussed the signalling pathway for the activation of Ras protein, the role of Ras in immunity and inflammation, downstream regulators of Ras protein and their inhibitors epigenetic regulation of Ras protein. Moreover, we have also done a database-based search using the Database of Cancer Mutant Protein Domains (DCMP) to find out the single nucleotide polymorphism (SNP) level of the Ras gene in different types of cancer. In terms of future perspective, this review discussed emerging strategies to target Ras protein.

摘要

癌症是21世纪最可怕的疾病之一,它是由不受控制的炎症反应和基因突变引起的。在人类癌症中,在各种突变基因中,Ras基因是最常发生突变的致癌基因之一。然而,说到炎症,致癌性Ras突变体可以在不依赖炎症反应导致的肿瘤抑制丧失的情况下诱导肿瘤发生。Ras蛋白是一种具有内在GTPase活性的膜结合蛋白,它被多种细胞外刺激激活,从无活性形式转变为活性形式。致癌性Ras突变体在癌症中持续被激活,从而增强导致肿瘤发生的异常下游信号传导。因此,为了突出Ras蛋白在癌症和炎症中的重要性,本综述讨论了Ras蛋白激活的信号通路、Ras在免疫和炎症中的作用、Ras蛋白的下游调节因子及其抑制剂、Ras蛋白的表观遗传调控。此外,我们还使用癌症突变蛋白结构域数据库(DCMP)进行了基于数据库的搜索,以找出不同类型癌症中Ras基因的单核苷酸多态性(SNP)水平。从未来展望的角度来看,本综述讨论了靶向Ras蛋白的新兴策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/95cd1caebe61/12672_2025_2783_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/e0f762d12441/12672_2025_2783_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/567588e1361d/12672_2025_2783_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/498c7aa5527b/12672_2025_2783_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/95cd1caebe61/12672_2025_2783_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/e0f762d12441/12672_2025_2783_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/567588e1361d/12672_2025_2783_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/498c7aa5527b/12672_2025_2783_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/369d/12145382/95cd1caebe61/12672_2025_2783_Fig4_HTML.jpg

相似文献

1
Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.阐明Ras蛋白作为炎症和癌症的双重治疗靶点:综述
Discov Oncol. 2025 Jun 7;16(1):1029. doi: 10.1007/s12672-025-02783-x.
2
KRAS: From undruggable to a druggable Cancer Target.KRAS:从不可成药到可成药的癌症靶点。
Cancer Treat Rev. 2020 Sep;89:102070. doi: 10.1016/j.ctrv.2020.102070. Epub 2020 Jul 15.
3
Sec5 and Exo84 foster oncogenic ras-mediated tumorigenesis.Sec5 和 Exo84 促进致癌 ras 介导的肿瘤发生。
Mol Cancer Res. 2010 Feb;8(2):223-31. doi: 10.1158/1541-7786.MCR-09-0189. Epub 2010 Feb 9.
4
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling.KSR非活性状态的小分子稳定作用可拮抗致癌性Ras信号传导。
Nature. 2016 Sep 1;537(7618):112-116. doi: 10.1038/nature19327. Epub 2016 Aug 24.
5
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.RAS 核苷酸循环是 SHP2 磷酸酶依赖性突变 BRAF、NF1 和 RAS 驱动癌症的基础。
Nat Cell Biol. 2018 Sep;20(9):1064-1073. doi: 10.1038/s41556-018-0169-1. Epub 2018 Aug 13.
6
Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers.一种受钙离子调节的Ras GTP酶激活蛋白RASAL的表观遗传沉默定义了人类癌症中Ras激活的一种新机制。
Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12353-8. doi: 10.1073/pnas.0700153104. Epub 2007 Jul 18.
7
RAS-mediated oncogenic signaling pathways in human malignancies.人类恶性肿瘤中 RAS 介导的致癌信号通路。
Semin Cancer Biol. 2019 Feb;54:1-13. doi: 10.1016/j.semcancer.2018.03.001. Epub 2018 Mar 7.
8
The GAP1 family of GTPase-activating proteins: spatial and temporal regulators of small GTPase signalling.GTP酶激活蛋白的GAP1家族:小GTP酶信号传导的时空调节因子
Biochem Soc Trans. 2006 Nov;34(Pt 5):846-50. doi: 10.1042/BST0340846.
9
The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.调控设计对表皮生长因子受体介导的信号转导对致癌突变反应的影响。
FEBS J. 2007 Nov;274(21):5505-17. doi: 10.1111/j.1742-4658.2007.06066.x. Epub 2007 Oct 4.
10
Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.抗体靶向细胞内致癌 Ras 突变体在系统给药后发挥抗肿瘤作用。
Nat Commun. 2017 May 10;8:15090. doi: 10.1038/ncomms15090.

本文引用的文献

1
Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.肺癌中基因、表观遗传和代谢改变的分子机制。
Med Oncol. 2025 Feb 2;42(3):61. doi: 10.1007/s12032-025-02608-5.
2
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors.量子计算增强算法揭示潜在的KRAS抑制剂。
Nat Biotechnol. 2025 Jan 22. doi: 10.1038/s41587-024-02526-3.
3
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy.KRAS在癌症代谢、肿瘤微环境及临床治疗中的作用。
Mol Cancer. 2025 Jan 13;24(1):14. doi: 10.1186/s12943-024-02218-1.
4
V-ATPase in cancer: mechanistic insights and therapeutic potentials.癌症中的V-ATP酶:机制见解与治疗潜力
Cell Commun Signal. 2024 Dec 20;22(1):613. doi: 10.1186/s12964-024-01998-9.
5
Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer.纳米颗粒介导的胰腺癌基因递送与免疫调节疗法的新见解与展望
J Nanobiotechnology. 2024 Dec 19;22(1):771. doi: 10.1186/s12951-024-02975-7.
6
Oncogenic RAS in Cancers from the DNA Replication Stress and Senescence Perspective.从DNA复制应激和衰老角度看癌症中的致癌RAS
Cancers (Basel). 2024 Nov 28;16(23):3993. doi: 10.3390/cancers16233993.
7
The Epigenetic Hallmarks of Cancer.癌症的表观遗传标志。
Cancer Discov. 2024 Oct 4;14(10):1783-1809. doi: 10.1158/2159-8290.CD-24-0296.
8
Tiam1 regulates proliferation, invasion, and differentiation in neuroblastoma through the Tiam1/Rac1 signaling pathway.Tiam1 通过 Tiam1/Rac1 信号通路调节神经母细胞瘤的增殖、侵袭和分化。
Neoplasma. 2024 Feb;71(1):37-47. doi: 10.4149/neo_2024_221217N1184. Epub 2024 Jan 23.
9
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development.将GAP与RAS突变体结合:癌症药物开发中一个老问题的新方法。
Int J Mol Sci. 2024 Feb 22;25(5):2572. doi: 10.3390/ijms25052572.
10
Pancreatic Cancer Treatment Targeting the HGF/c-MET Pathway: The MEK Inhibitor Trametinib.靶向HGF/c-MET通路的胰腺癌治疗:MEK抑制剂曲美替尼
Cancers (Basel). 2024 Mar 5;16(5):1056. doi: 10.3390/cancers16051056.